QQQ
Invesco QQQ Trust, Series 1
The hourly resistance level was created at 10:30 when price action fell below $732.20. Price action is nearing the daily distribution trend and hourly resistance level at $740.16 which could be a target later this week. A FrontSide support level sits at $718.47, a candle created Aug 11 at 11:30 which is part of the hourly accumulation trend. The $718.47 level is the last hourly support level in the range. A weekly support level is at $724.36 and if strength favors the higher timeframe, then the hourly level at $718.47 is backed up by the higher timeframe liquidity if it's there. A long wick to 718 and the body closes over 724 would be a bullish scenario to break a daily distribution trend. if not, the other weekly support levels are there and next couple weeks might feel slow as some rebalance portfolio's and account for portfolio drift over the last quarter.
Sunny Sanyal
· HealthcarePersonal Background
Sunny Sanyal holds a Bachelor of Engineering in Electrical Engineering from the University of Mumbai, a Master of Science in Industrial Engineering from Louisiana State University, and an MBA from Harvard Business School. He is a resident of Sandy, Utah, and is known for a lifestyle that includes skiing and traveling. He was named "CEO of the Year" by BioUtah in 2021 for his leadership during the pandemic and his commitment to innovation.
Business Background
Before becoming the founding CEO of Varex in 2017, Sanyal was the Senior Vice President and President of Varian Medical Systems’ Imaging Components business. His extensive executive resume includes roles as CEO of T-System, President of McKesson Provider Technologies, and Vice President/General Manager at GE Healthcare. His vision has been to transition Varex from a component supplier to a holistic "imaging solutions" provider. He has championed "independent supplier" status to serve all major OEMs and has aggressively invested in "next-gen" X-ray technologies like photon-counting and multi-beam X-ray (MBX). Most recently, he steered the company toward a definitive merger agreement with Teledyne Technologies, announced in August 2026.
Company Facts
- • Varex is the world’s largest independent supplier of medical X-ray tubes and image processing solutions, serving nearly every major medical imaging OEM globally.
- • Through its Pyxis™ platform, Varex is a leader in photon-counting CT technology, which allows for "spectral" imaging—effectively giving doctors the ability to see X-rays in "color" to better distinguish between different types of tissues.
- • Their Multi-Beam X-ray (MBX) technology is revolutionary because it replaces mechanical rotation in X-ray systems with electronically controlled beams, allowing for faster, more robust 3D imaging.
- • While medical imaging is their core, Varex components are critical to global security; they power the high-energy cargo inspection systems used at international ports and borders to detect contraband.
- • The company traces its roots back to the 1930s (Eimac Products) and was a key division of Varian Medical Systems for decades before spinning off as an independent public entity in 2017.
- • Varex operates a massive global supply chain with manufacturing and R&D facilities in the U.S., Germany, the Netherlands, Sweden, Finland, the Philippines, and recently expanded operations in India.
- • On August 10, 2026, it was announced that Teledyne Technologies (TDY) would acquire Varex in an all-cash deal valued at $1.1 billion ($18.90 per share), highlighting Varex's unique value in the sensor and imaging market.
Personal Vision
Q1. Sunny, you’ve led Varex from its birth as a spin-off to this massive $1.1 billion deal with Teledyne. Looking back at your career at GE, McKesson, and Varian, what is the single most important leadership lesson you applied to make Varex a standalone success?
—
Q2. You were named CEO of the Year by BioUtah in 2021. During the height of global supply chain disruptions, how did your background in industrial engineering help you keep the production lines moving for critical medical components?
—
Q3. How do you personally balance the need for high-stakes corporate strategy with the innovative "tinkering" spirit required in a deep-tech company like Varex?
—
Business Vision
Q1. Varex has been described as a "Switzerland" in the imaging world—an independent supplier to everyone. How does joining a massive conglomerate like Teledyne affect that neutral, independent market position?
—
Q2. Multi-Beam X-ray (MBX) technology is a significant departure from 100 years of X-ray history. Can you explain for our audience how replacing mechanical motion with electronic beams changes the patient experience in a CT scanner?
—
Q3. You’ve recently expanded manufacturing into India and dealt with complex tariff environments in China. What does the "post-merger" global footprint of Varex look like under the Teledyne umbrella?
—
Why Buy Their Stock
Q1. With the Teledyne acquisition offer at $18.90 per share, the market saw a massive 48% surge. For investors still holding VREX or looking at the arbitrage, why is this $1.1 billion valuation a fair reflection of Varex’s long-term R&D pipeline?
—
Q2. Beyond the medical sector, Varex has a growing industrial and security business. How much of the "investment case" for Varex relies on the increasing need for high-tech cargo screening at global borders, and how does that diversify the risk for shareholders?
—
Share This Post